Targeting
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carcinoma, Transitional Cell
/ drug therapy
Chemotherapy, Adjuvant
Humans
Phenylurea Compounds
/ therapeutic use
Pyrimidines
Randomized Controlled Trials as Topic
Receptor, Fibroblast Growth Factor, Type 3
/ genetics
Urinary Bladder Neoplasms
/ drug therapy
FGFR inhibitor
FGFR3
PROOF 302
adjuvant cisplatin-based chemotherapy
adjuvant therapy
cisplatin-therapy refusal
fusions or rearrangements
infigratinib
muscle-invasive urothelial carcinoma
mutations
neoadjuvant cisplatin-based chemotherapy
phase III
upper tract urothelial carcinoma
urothelial bladder carcinoma
urothelial carcinoma
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
pubmed:
25
5
2022
medline:
18
6
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible Cancers of the bladder and other parts in the urinary system, especially those that are invasive and grow into the muscle layer, may need extra treatment after surgical removal of the tumor, particularly if there is a high risk of the cancer coming back. Chemotherapy regimens that include cisplatin are often used postoperatively, although some patients are unable to tolerate this treatment or refuse it. FGFR3, a protein that is encoded by the
Autres résumés
Type: plain-language-summary
(eng)
Cancers of the bladder and other parts in the urinary system, especially those that are invasive and grow into the muscle layer, may need extra treatment after surgical removal of the tumor, particularly if there is a high risk of the cancer coming back. Chemotherapy regimens that include cisplatin are often used postoperatively, although some patients are unable to tolerate this treatment or refuse it. FGFR3, a protein that is encoded by the
Identifiants
pubmed: 35608106
doi: 10.2217/fon-2021-1629
doi:
Substances chimiques
Phenylurea Compounds
0
Pyrimidines
0
infigratinib
A4055ME1VK
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT04197986']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2599-2614Subventions
Organisme : QED Therapeutics
Organisme : Helsinn Healthcare S.A.